checkAd

     107  0 Kommentare Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

    Relief Therapeutics Holding SA / Key word(s): Research Update
    Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

    07-Nov-2022 / 07:00 CET/CEST
    Release of an ad hoc announcement pursuant to Art. 53 LR
    The issuer is solely responsible for the content of this announcement.


    Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

    This new formulation may have important clinical uses for a variety of rare lung diseases

    Geneva, Switzerland, November 7, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing, and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced promising six-month stability data on a new formulation of RLF-100 (aviptadil). The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperature environments. The results are consistent with those observed at the three-month time period. Based on these results, Relief has filed a new provisional patent application.

    “The testing conducted to date has shown our novel RLF-100 formulation to be shelf-stable at temperatures suitable for shipping and long-term storage, a critical step towards commercialization,” stated Raghuram (Ram) Selvaraju, Ph.D., Chairman of the Board of Directors of Relief. “We believe that this new, stable formulation has significant clinical and commercial value, and may allow RLF-100 to be delivered via multiple routes of administration for treatment of several debilitating lung disease indications including pulmonary sarcoidosis, acute respiratory distress syndrome (“ARDS”), berylliosis and checkpoint inhibitor-induced pneumonitis (“CIP”), all of which Relief plans to pursue. As previously reported, we intend to initiate a Phase 2b dose ranging study in 54 patients with pulmonary sarcoidosis using inhaled RLF-100 administered over a 12-week period. A pre-IND meeting with the U.S. Food and Drug Administration (FDA) is planned to confirm the efficacy and safety endpoints as well as the proposed dosing regimen and, based on a positive outcome, the trial is expected to begin during 2023.”

    Seite 1 von 4


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) Relief Therapeutics Holding SA / Key word(s): Research Update Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) 07-Nov-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR …

    Schreibe Deinen Kommentar

    Disclaimer